Metarrestin slows spread of ovarian cancerDecember 13, 2018
A novel anti-cancer drug, ML246 (metarrestin), reveals its ability to attenuate the growth and progression of ovarian cancer. The study conducted by Kanis et al reports for the first time on the effects of ML246, an inhibitor of the perinucleolar compartment (PNC), in ovarian cancer cells. PNCs were detected in the human ovarian cancer cell lines, SKOV3 and OVCAR3, which were treated with ML246 for its invasive activity in vitro and was tested for its efficacy on tumour growth and spread in xenograft mice models in vivo. The results showed a remarkable decrease in the invasive ability of ovarian cancer cell lines and attenuated the growth of tumour in human xenografts of ovarian cancer which reduced the abdominal spread of the xenografts. The study data demonstrate ML246 is as effective as cisplatin in inhibiting ovarian cancer growth and thus suggests its utility in platinum-resistant disease. These data warrant additional investigation into the therapeutic potential of ML246 for ovarian cancer as well as its mode of action while showing PNC structure as a potential reliable target in treating ovarian cancer.
Source: Gynecologic Oncology Research and Practice20185:7 2nd October 2018 https://doi.org/10.1186/s40661-018-0064-2 /